Investors & Media Press Releases

Press Releases

Summary Toggle

04.08.2020

Summary Toggle Axovant Provides Business and Operations Update During the COVID-19 Pandemic

Summary ToggleCompleted dosing of all patients in second cohort of AXO-Lenti-PD dose escalation study At present, Company remains on track to achieve key 2020 milestones NEW YORK and BASEL, Switzerland , April 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd.
Read More

PDF Version
Read More
Summary Toggle

03.31.2020

Summary Toggle Axovant to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

Summary ToggleNEW YORK and BASEL, Switzerland , March 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that management will participate in the virtual Guggenheim Healthcare Talks:
Read More

PDF Version
Read More
Summary Toggle

02.24.2020

Summary Toggle Axovant Gene Therapies Announces Closing of $74.7 Million Public Offering of Common Shares and Prefunded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Summary ToggleNEW YORK and BASEL, Switzerland , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the closing of its previously announced underwritten public offering of 16,631,336 common shares, including the full exercise of the underwriters’ option to
Read More

PDF Version
Read More
Summary Toggle

02.19.2020

Summary Toggle Axovant Gene Therapies Announces Pricing of $65 Million Public Offering

Summary ToggleNEW YORK and BASEL, Switzerland , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 14,031,336 of its common shares at a price to the public of $3.75 per share.
Read More

PDF Version
Read More
Summary Toggle

02.19.2020

Summary Toggle Axovant Gene Therapies Announces Commencement of Public Offering

Summary ToggleNEW YORK and BASEL, Switzerland , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares and pre-funded warrants to purchase its common shares.
Read More

PDF Version
Read More
Summary Toggle

02.10.2020

Summary Toggle Axovant Announces Financial Results for Third Fiscal Quarter and Nine Months Ended December 31, 2019

Summary ToggleNEW YORK and BASEL, Switzerland , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today provided financial results for its third fiscal quarter ended December 31, 2019 .
Read More

PDF Version
Read More
Summary Toggle

01.13.2020

Summary Toggle Axovant Announces Positive 12-month Data on AXO-Lenti-PD and Provides Updates Across Gene Therapy Pipeline Programs

Summary ToggleNEW YORK and BASEL, Switzerland, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced recent progress in its gene therapy programs, including a 12-month update on its
Read More

PDF Version
Read More
Summary Toggle

12.19.2019

Summary Toggle Axovant Provides Clinical Program Update for AXO-AAV-GM1, a Novel Investigational Gene Therapy for GM1 Gangliosidosis

Summary ToggleNEW YORK and BASEL, Switzerland , Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT) today announced preliminary findings from an expanded access treatment in which a single patient with GM1 gangliosidosis was administered investigational AXO-AAV-GM1 gene therapy.
Read More

PDF Version
Read More
Summary Toggle

12.03.2019

Summary Toggle Axovant Announces Amendment to Credit Facility with Hercules Capital

Summary ToggleNEW YORK and BASEL, Switzerland , Dec. 03, 2019 (GLOBE NEWSWIRE) -- New loan amendment reduces loan obligation by 50% without penalty, eliminates minimum cash covenant, and extends interest-only period for 9 months Debt service burden reduced by approximately $2.0 million per month during
Read More

PDF Version
Read More
Summary Toggle

11.18.2019

Summary Toggle Axovant Gene Therapies Receives Orphan Drug Designation from FDA for AXO-AAV-GM1 for the Treatment of GM1 Gangliosidosis

Summary ToggleNEW YORK and BASEL, Switzerland , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Administration ( FDA ) has granted orphan drug designation for the Company’s
Read More

PDF Version
Read More

Investors & Media Press Releases

Press Releases

Email Alerts

Print

Email

Search

Investors & Media Press Releases

Press Releases

Toolbar

Email Alerts

Print

Email

Search